Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.10) by 41.18 percent. This is a 45.45 percent increase over losses of $(0.11) per share from the same period last year.